ANTICOAGULANT THROMBINS IN VITRO AND IN VIVO

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。促凝血剂需要Na+结合，但凝血酶的抗凝血活性不需要。这一发现使我们能够设计出新的凝血酶类似物，选择性地降低它们的促凝血特性。我们开始在灵长类动物模型设计器中测试对天然抗凝剂蛋白C具有高选择性的酶，以评估它们对血栓形成和止血的影响。与预测一致的是，几个分子显示出抗凝和抗血栓作用。我们一直在将这些突变体中的一些与直接使用活化蛋白C和其他抗血栓药物的效果进行比较。最近完成的一系列研究揭示了蛋白C激活酶W215A/E217A的药理潜力，它是一种36kD的凝血酶类似物。在我们的灵长类动物模型中，W215A/E217A在防止血栓形成方面比公认的抗凝剂依诺肝素强两到三个数量级，而且明显更安全。事实上，W215A/E217A是迄今已知的最有效的抗血栓分子。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Na+ binding is required for the procoagulant, but not the anticoagulant activity of thrombin. This discovery has enabled us to engineer novel thrombin analogs selectively compromised in their procoagulant properties. We started testing in our primate model designer enzymes with high selectivity toward the natural anticoagulant, protein C, to assess their effects on thrombosis and hemostasis. Consistent with the predictions, several molecules have shown anticoagulant and antithrombotic effects. We have been comparing the effects of some of these mutants with the direct administration of activated protein C and other antithrombotic agents. The latest completed series of studies revealed the pharmacological potential of the protein C activator enzyme, W215A/E217A, which is a 36kD thrombin analog. W215A/E217A proved to be two to three orders of magnitude more potent and significantly safer in our primate model than an accepted anticoagulant, enoxaparin, in the prevention of thrombus formation. In fact, W215A/E217A is the most potent antithrombotic molecule known to date.